A5083477114- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Microtubule and mitosis dynamics
- Neuroendocrine Tumor Research Advances
- Head and Neck Cancer Studies
- Immunotherapy and Immune Responses
- Pancreatic and Hepatic Oncology Research
- Vitamin C and Antioxidants Research
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- PARP inhibition in cancer therapy
- Effects of Radiation Exposure
- Cancer therapeutics and mechanisms
- Immune Cell Function and Interaction
- Vitamin D Research Studies
- Gut microbiota and health
- Edcuational Technology Systems
- Chronic Lymphocytic Leukemia Research
- Glioma Diagnosis and Treatment
- Cytokine Signaling Pathways and Interactions
Edinburgh Cancer Research
2024-2025
University of Iowa
2015-2025
New York Medical College
2013-2025
Westchester Medical Center
2013-2025
Lahore University of Management Sciences
2018-2025
Kohat University of Science and Technology
2025
Trinity College Dublin
2025
Western General Hospital
2025
University of Edinburgh
2024
University of Iowa Hospitals and Clinics
2015-2024
Pancreatic and colorectal cancers are often KRAS mutated incurable when tumor DNA or protein persists recurs after curative intent therapy. Cancer vaccine ELI-002 2P enhances lymph node delivery immune response using amphiphile (Amph) modification of G12D G12R mutant (mKRAS) peptides (Amph-Peptides-2P) together with CpG oligonucleotide adjuvant (Amph-CpG-7909). We treated 25 patients (20 pancreatic five colorectal) who were positive for minimal residual mKRAS disease (ctDNA and/or serum...
Abstract Fibroblast growth factor receptor ( FGFR ) alterations drive oncogenesis in multiple tumor types. Here we studied pemigatinib, a selective, potent, oral FGFR1–FGFR3 inhibitor, the phase 2 FIGHT-207 basket study of FGFR- altered advanced solid tumors. Primary end points were objective response rate (ORR) cohorts A (fusions/rearrangements, n = 49) and B (activating non-kinase domain mutations, 32). Secondary progression-free survival, duration overall survival B, safety. Exploratory...
JAK-STAT (Janus associated kinase-signal transducer and activator of transcription) pathway plays a critical role in transduction extracellular signals from cytokines growth factors involved hematopoiesis, immune regulation, fertility, lactation, embryogenesis. JAK family contains four cytoplasmic tyrosine kinases, JAK1-3 Tyk2. Seven STAT proteins have been identified human cells, STAT1-6, including STAT5a STAT5b. Negative regulators pathways include phosphatases (SHP1 2, CD45), protein...
Abstract Purpose: Seizure-related homolog protein 6 (SEZ6) is a novel target expressed in small cell lung cancer (SCLC). ABBV-011, SEZ6-targeted antibody conjugated to calicheamicin, was evaluated phase I study (NCT03639194) patients with relapsed/refractory SCLC. We report initial outcomes of ABBV-011 monotherapy. Patients and Methods: administered intravenously once every 3 weeks during dose escalation (0.3–2 mg/kg) expansion. SEZ6-positive tumors (≥25% tumor cells ≥1+ staining intensity...
Though the gut microbiome has been associated with efficacy of immunotherapy (ICI) in certain cancers, similar findings have not identified for microbiomes from other body sites and their correlation to treatment response immune related adverse events (irAEs) lung cancer (LC) patients receiving ICIs.We designed a prospective cohort study conducted 2018 2020 at single-center academic institution assess correlations between various development irAEs LC treated ICIs. Patients must had...
We conducted a phase I, multicenter, open-label, dose-finding, and expansion study to determine the safety preliminary efficacy of eprenetapopt (APR-246) combined with pembrolizumab in patients advanced/metastatic solid tumors (ClinicalTrials.gov NCT04383938).For requirements were non-central nervous system primary tumor, intolerant to/progressed after ≥1 line treatment, eligible for pembrolizumab; expansion: (i) gastric/gastroesophageal junction first-line no prior anti-programmed cell...
Breast cancer is the leading cause of morbidity and mortality globally but has an even more significant impact in developing countries. Pakistan highest prevalence among Asian A general lack public awareness regarding disease often results late diagnosis poor treatment outcomes. The literacy rate Southern Punjab (Pakistan) low compared to its Northern part. It therefore vital that university students especially medical develop a sound knowledge about so they can spread others who may be less...
Background: We conducted a multicenter, randomized trial of early integrated palliative and oncology care in patients with advanced cancer to confirm the benefits (PC) seen prior single-center studies. Methods: randomly assigned newly diagnosed incurable (n = 195) or usual 196) at sites through Alliance for Clinical Trials Oncology. Patients intervention were expected meet PC clinician least monthly until death, whereas consulted on request. The primary endpoint was change quality life from...
Platinum-based chemotherapy with or without immunotherapy is the mainstay of treatment for advanced stage non-small cell lung cancer (NSCLC) lacking a molecular driver alteration. Pre-clinical studies have reported that pharmacological ascorbate (P-AscH-) enhances NSCLC response to platinum-based therapy. We conducted phase II clinical trial combining P-AscH- carboplatin-paclitaxel chemotherapy.Chemotherapy naïve patients received 75 g twice per week intravenously carboplatin and paclitaxel...
3002 Background: Small cell lung cancer (SCLC) has a dismal prognosis and new therapies are urgently needed. SEZ6 is transmembrane protein expressed in SCLC tumors that may be used as therapeutic target. ABBV-011 an antibody-drug conjugate (ADC) targeting with calicheamicin payload, which shown antitumor activity preclinical models of SCLC. Preliminary results from the monotherapy dose-escalation -expansion cohorts first-in-human study presented. Methods: Phase 1, open-label, multicenter...
PurposeThe adrenal glands are a common site of metastases because their rich blood supply. Previously, were treated with systemic chemotherapy or, more rarely, surgical resection or palliative radiation therapy. Stereotactic body therapy (SBRT) has recently emerged as an attractive noninvasive approach to definitively treat these lesions. We present our experience in treating using SBRT and review the current literature.Methods materialsThis is single-institution retrospective patients who...
Head and neck squamous cell carcinoma (HNSCC) patients treated with high-dose cisplatin concurrently radiotherapy (hdCis-RT) commonly suffer kidney injury leading to acute chronic disease (AKD CKD, respectively). We conducted a retrospective analysis of renal function injury-related plasma biomarkers in subset HNSCC subjects receiving hdCis-RT double-blinded, placebo-controlled clinical trial (NCT02508389) evaluating the superoxide dismutase mimetic, avasopasem manganese (AVA), an...
2528 Background: RAS mutations occur in 25% of solid tumors with G12D being the most frequent variant. ELI-002 2P is a vaccine comprised lymph-node targeted Amphiphile (Amph)-modified and G12R mutant KRAS peptides an Amph-modified CpG oligonucleotide adjuvant designed to expand polyfunctional KRAS-specific T cells. Preclinical amphiphile data (relative non-amphiphile controls) showed increased immunogenicity, tumor clearance survival mouse models. Methods: This first-in-human multicenter...
Abstract Background: Fibroblast growth factor receptor (FGFR) alterations are promising targets in different tumors. We report results of FIGHT-207, an open-label, single-arm phase 2 study pemigatinib, a potent, selective FGFR1-3 inhibitor, patients with previously treated unresectable or metastatic FGFR-altered solid tumors (NCT03822117). Methods: Patients were assigned to cohorts A (FGFR1-3 fusions), B activating non-kinase domain mutations), and C kinase mutations unknown significance)...
Elderly cancer patients treated with ionizing radiation (IR) or chemotherapy experience more frequent and greater normal tissue toxicity relative to younger patients. The current study demonstrates that exponentially growing fibroblasts from elderly (old) male donor subjects (70, 72, 78 years) are significantly sensitive clonogenic killing mediated by platinum-based IR (∼70%-80% killing) young (5 months 1 year; ∼10%-20% adult (20 years old; ∼10%-30% killing). Old also displayed increased...